The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-Cell lymphoma referred for CD19-directed CAR T-Cell therapy in The Netherlands

Simple Summary CAR T-cell therapy has emerged as the new standard of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but real-world outcomes differ across countries. Additionally, real-world data on health-related quality of life (HR-QoL) are scarce but important, as they reflect the direct experience of patients. In the Netherlands, patients can be referred to the CAR-T tumorboard, a national CAR-T expert panel, who decide whether CAR-T is a feasible treatment option. This multicenter study reports on the favorable outcomes, including the HR-QoL, of axicabtagene ciloleucel (axi-cel) for patients with R/R LBCL after & GE;2 lines of systemic therapy in the Netherlands. On the other hand, we show that a substantial proportion of patients are still in need of alternative treatments, including improved CAR-T strategies, as they are unfit for or do not respond to axi-cel. Comparing real-world outcomes between cohorts could help to select best practices and further optimize CAR-T treatment.Abstract The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after & GE;2 lines of systemic therapy referred for axi-cel treatment between May 2020-May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need.Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological disease

Comparative performance analysis of Passivhaus and building regulation certified properties built in the United Kingdom

This paper compares the energy performance of Passivhaus and Building Regulations certified properties constructed in the UK. The Passivhaus criteria and construction principles are explained and the certification criteria for both standards are rationalised for a direct comparison. Relevant data was collected from case studies, building certifications, and the approved local planning submissions. The results reveal that, on average, Passivhaus properties were twice as thermally efficient from a numeric U-value standpoint, though are likely to perform even better due to the construction quality standards. This notion is backed up by the overall energy savings which on average come out to 75% compared to a conventionally built home

The Scale Analysis of Bivariate Non-Gaussian Time Series via Wavelet Cross-Covariance

this paper we study the scale analysis of bivariate time series through use of the wavelet cross-covariance. If